Does the media refer more to MIRM or IOVA?

In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat Mirum Pharmaceuticals' score of 0.78 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mirum Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PTCT or IOVA?

In the previous week, PTC Therapeutics had 9 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 12 mentions for PTC Therapeutics and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat PTC Therapeutics' score of 0.57 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PTC Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IOVA or COGT?

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 3 articles in the media. Cogent Biosciences' average media sentiment score of 1.60 beat Iovance Biotherapeutics' score of 0.82 indicating that Cogent Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cogent Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media prefer LNTH or IOVA?

In the previous week, Lantheus had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Iovance Biotherapeutics. Lantheus' average media sentiment score of 1.19 beat Iovance Biotherapeutics' score of 0.82 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to SRRK or IOVA?

In the previous week, Scholar Rock had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 13 mentions for Scholar Rock and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat Scholar Rock's score of -0.10 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 2 Very Positive mention(s) 5 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iovance Biotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Iovance Biotherapeutics (IOVA) Competitors

$4.23 -0.14 (-3.20%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$4.26 +0.03 (+0.71%)

As of 07/10/2026 07:57 PM Eastern

Compare

IOVA vs. MIRM, PTCT, COGT, LNTH, and SRRK

Should you buy Iovance Biotherapeutics stock or one of its competitors? MarketBeat compares Iovance Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Iovance Biotherapeutics include Mirum Pharmaceuticals (MIRM), PTC Therapeutics (PTCT), Cogent Biosciences (COGT), Lantheus (LNTH), and Scholar Rock (SRRK). These companies are all part of the "pharmaceutical products" industry.

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

Mirum Pharmaceuticals has higher revenue and earnings than Iovance Biotherapeutics. Mirum Pharmaceuticals is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mirum Pharmaceuticals	$521.31M	14.29	-$23.36M	-$13.61	N/A
Iovance Biotherapeutics	$263.50M	7.17	-$390.98M	-$0.95	N/A

Iovance Biotherapeutics has a net margin of -123.92% compared to Mirum Pharmaceuticals' net margin of -140.24%. Mirum Pharmaceuticals' return on equity of -11.28% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mirum Pharmaceuticals	-140.24%	-11.28%	-3.84%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Mirum Pharmaceuticals has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, indicating that its stock price is 30% less volatile than the broader market.

In the previous week, Mirum Pharmaceuticals had 8 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 11 mentions for Mirum Pharmaceuticals and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat Mirum Pharmaceuticals' score of 0.78 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mirum Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mirum Pharmaceuticals currently has a consensus price target of $143.40, suggesting a potential upside of 17.42%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 99.26%. Given Iovance Biotherapeutics' higher possible upside, analysts plainly believe Iovance Biotherapeutics is more favorable than Mirum Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mirum Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

77.0% of Iovance Biotherapeutics shares are held by institutional investors. 8.3% of Mirum Pharmaceuticals shares are held by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Mirum Pharmaceuticals beats Iovance Biotherapeutics on 10 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to PTC Therapeutics?

PTC Therapeutics (NASDAQ:PTCT) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, PTC Therapeutics had 9 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 12 mentions for PTC Therapeutics and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat PTC Therapeutics' score of 0.57 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PTC Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PTC Therapeutics has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 5.5% of PTC Therapeutics shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

PTC Therapeutics has higher revenue and earnings than Iovance Biotherapeutics. PTC Therapeutics is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PTC Therapeutics	$827.11M	8.51	$682.64M	-$2.33	N/A
Iovance Biotherapeutics	$263.50M	7.17	-$390.98M	-$0.95	N/A

PTC Therapeutics has a net margin of -22.58% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat PTC Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PTC Therapeutics	-22.58%	-362.45%	-6.76%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

PTC Therapeutics currently has a consensus target price of $91.57, suggesting a potential upside of 7.92%. Iovance Biotherapeutics has a consensus target price of $8.43, suggesting a potential upside of 99.26%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than PTC Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PTC Therapeutics	2 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.80
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Summary

PTC Therapeutics beats Iovance Biotherapeutics on 9 of the 17 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Iovance Biotherapeutics (NASDAQ:IOVA) and Cogent Biosciences (NASDAQ:COGT) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Iovance Biotherapeutics currently has a consensus price target of $8.43, suggesting a potential upside of 99.26%. Cogent Biosciences has a consensus price target of $43.73, suggesting a potential upside of 12.50%. Given Iovance Biotherapeutics' higher possible upside, research analysts clearly believe Iovance Biotherapeutics is more favorable than Cogent Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30
Cogent Biosciences	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86

Cogent Biosciences has lower revenue, but higher earnings than Iovance Biotherapeutics. Cogent Biosciences is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Iovance Biotherapeutics	$263.50M	7.17	-$390.98M	-$0.95	N/A
Cogent Biosciences	N/A	N/A	-$328.94M	-$2.17	N/A

77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 7.8% of Iovance Biotherapeutics shares are owned by insiders. Comparatively, 6.6% of Cogent Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Cogent Biosciences has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Cogent Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%
Cogent Biosciences	N/A	-104.27%	-54.64%

Iovance Biotherapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market. Comparatively, Cogent Biosciences has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

In the previous week, Iovance Biotherapeutics and Iovance Biotherapeutics both had 3 articles in the media. Cogent Biosciences' average media sentiment score of 1.60 beat Iovance Biotherapeutics' score of 0.82 indicating that Cogent Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cogent Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Iovance Biotherapeutics beats Cogent Biosciences on 9 of the 15 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, risk, profitability, institutional ownership, analyst recommendations and media sentiment.

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Iovance Biotherapeutics' net margin of -123.92%. Lantheus' return on equity of 29.32% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Lantheus currently has a consensus target price of $108.29, suggesting a potential upside of 2.50%. Iovance Biotherapeutics has a consensus target price of $8.43, suggesting a potential upside of 99.26%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

In the previous week, Lantheus had 1 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 4 mentions for Lantheus and 3 mentions for Iovance Biotherapeutics. Lantheus' average media sentiment score of 1.19 beat Iovance Biotherapeutics' score of 0.82 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus has a beta of -0.06, suggesting that its stock price is 106% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, suggesting that its stock price is 30% less volatile than the broader market.

Lantheus has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.46	$233.56M	$4.15	25.46
Iovance Biotherapeutics	$263.50M	7.17	-$390.98M	-$0.95	N/A

Summary

Lantheus beats Iovance Biotherapeutics on 12 of the 16 factors compared between the two stocks.

How does Iovance Biotherapeutics compare to Scholar Rock?

Scholar Rock (NASDAQ:SRRK) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, media sentiment, valuation, earnings, analyst recommendations, institutional ownership and profitability.

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 13.3% of Scholar Rock shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scholar Rock has a beta of 0.67, meaning that its share price is 33% less volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.7, meaning that its share price is 30% less volatile than the broader market.

Scholar Rock presently has a consensus price target of $56.00, suggesting a potential downside of 1.25%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 99.26%. Given Iovance Biotherapeutics' higher probable upside, analysts clearly believe Iovance Biotherapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	4 Strong Buy rating(s)	3.12
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Scholar Rock has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Iovance Biotherapeutics' return on equity of -50.17% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-163.52%	-96.67%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Scholar Rock has higher earnings, but lower revenue than Iovance Biotherapeutics. Scholar Rock is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.59	N/A
Iovance Biotherapeutics	$263.50M	7.17	-$390.98M	-$0.95	N/A

In the previous week, Scholar Rock had 10 more articles in the media than Iovance Biotherapeutics. MarketBeat recorded 13 mentions for Scholar Rock and 3 mentions for Iovance Biotherapeutics. Iovance Biotherapeutics' average media sentiment score of 0.82 beat Scholar Rock's score of -0.10 indicating that Iovance Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	2 Very Positive mention(s)	5 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Iovance Biotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Scholar Rock and Iovance Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Iovance Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IOVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IOVA vs. The Competition

Export

Metric	Iovance Biotherapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.95B	$3.76B	$7.14B	$12.64B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-4.45	21.83	27.42	24.58
Price / Sales	7.17	323.85	593.42	121.59
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	2.40	8.41	10.88	6.38
Net Income	-$390.98M	$23.85M	$3.59B	$331.87M
7 Day Performance	-1.86%	-0.75%	-0.26%	0.37%
1 Month Performance	6.68%	8.81%	4.52%	0.53%
1 Year Performance	126.20%	53.66%	29.17%	21.96%

Iovance Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IOVA Iovance Biotherapeutics	2.673 of 5 stars	$4.23 -3.2%	$8.43 +99.3%	+119.2%	$1.95B	$263.50M	N/A	500
MIRM Mirum Pharmaceuticals	2.7013 of 5 stars	$121.91 -2.9%	$143.00 +17.3%	+130.4%	$7.43B	$569.61M	N/A	140	Analyst Forecast Insider Trade
PTCT PTC Therapeutics	2.8156 of 5 stars	$85.44 +2.6%	$91.36 +6.9%	+71.3%	$7.09B	$1.73B	N/A	1,410	Analyst Upgrade Insider Trade High Trading Volume
COGT Cogent Biosciences	1.409 of 5 stars	$39.44 +1.9%	$43.73 +10.9%	+258.2%	$6.74B	N/A	N/A	80	News Coverage Positive News Analyst Forecast
LNTH Lantheus	3.2422 of 5 stars	$102.82 -6.4%	$101.86 -0.9%	+26.0%	$6.69B	$1.54B	24.78	1,193	News Coverage Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IOVA) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. MIRM, PTCT, COGT, LNTH, and SRRK

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Summary

How does Iovance Biotherapeutics compare to PTC Therapeutics?

Summary

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Summary

How does Iovance Biotherapeutics compare to Scholar Rock?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Iovance Biotherapeutics (IOVA) Competitors

IOVA vs. MIRM, PTCT, COGT, LNTH, and SRRK

How does Iovance Biotherapeutics compare to Mirum Pharmaceuticals?

Which has preferable earnings & valuation, MIRM or IOVA?

Is MIRM or IOVA more profitable?

Which has more volatility & risk, MIRM or IOVA?

Does the media refer more to MIRM or IOVA?

Do analysts recommend MIRM or IOVA?

Do institutionals & insiders hold more shares of MIRM or IOVA?

Summary

How does Iovance Biotherapeutics compare to PTC Therapeutics?

Does the media refer more to PTCT or IOVA?

Which has more risk & volatility, PTCT or IOVA?

Do institutionals & insiders hold more shares of PTCT or IOVA?

Which has higher earnings and valuation, PTCT or IOVA?

Is PTCT or IOVA more profitable?

Do analysts prefer PTCT or IOVA?

Summary

How does Iovance Biotherapeutics compare to Cogent Biosciences?

Do analysts rate IOVA or COGT?

Which has stronger earnings and valuation, IOVA or COGT?

Do insiders & institutionals hold more shares of IOVA or COGT?

Is IOVA or COGT more profitable?

Which has more volatility and risk, IOVA or COGT?

Does the media prefer IOVA or COGT?

Summary

How does Iovance Biotherapeutics compare to Lantheus?

Do insiders and institutionals hold more shares of LNTH or IOVA?

Is LNTH or IOVA more profitable?

Do analysts prefer LNTH or IOVA?

Does the media prefer LNTH or IOVA?

Which has more volatility and risk, LNTH or IOVA?

Which has stronger valuation & earnings, LNTH or IOVA?

Summary

How does Iovance Biotherapeutics compare to Scholar Rock?

Do institutionals & insiders hold more shares of SRRK or IOVA?

Which has more risk and volatility, SRRK or IOVA?

Do analysts recommend SRRK or IOVA?

Is SRRK or IOVA more profitable?

Which has stronger valuation and earnings, SRRK or IOVA?

Does the media refer more to SRRK or IOVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA vs. The Competition

Iovance Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools